"Real world" data show that safety and efficacy results with two transcatheter tricuspid valve repair systems mirror those seen in the clinical trials approvals were based on.
Three-fourths of patients had at least a two-grade reduction in tricuspid regurgitation, and 88% were alive 1 year after treatment with the experimental device.
/PRNewswire/ Peijia Medical (HKEX:9996, or "Peijia"), a leading player in China for medical technology, announced a partnership with inQB8, a Boston based.
/PRNewswire/ Peijia Medical (HKEX:9996, or "Peijia"), a leading player in China for medical technology, announced a partnership with inQB8, a Boston based.